Qugo Powder For Oral Solution
1 NAME OF THE MEDICINAL PRODUCT
Macrogol compound powder for oral solution Qugo Powder for Oral Solution
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each sachet contains the following quantitative composition of active ingredients:
Macrogol 3350 13.125 g
Sodium Chloride 0.3507 g
Sodium Hydrogen Carbonate 0.1785 g
Potassium Chloride 0.0466 g
The content of electrolyte ions per sachet following reconstitution in 125 ml of water is equivalent to:
Sodium 65 mmol/l
Chloride 53 mmol/l
Hydrogen Carbonate (Bicarbonate) 17 mmol/l Potassium 5 mmol/l
For a full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Powder for oral solution
Single-dose sachet containing a free flowing white powder.
4 CLINICAL PARTICULARS
4.1 Therapeutic indications
For the treatment of chronic constipation.
4.2 Posology and method of administration
Qugo Powder for Oral Solution/Macrogol compound powder for oral solution is for oral use.
A course of treatment for chronic constipation with Qugo Powder for Oral Solution / Macrogol compound powder for oral solution does not normally exceed 2 weeks, although this can be repeated if required. As for all laxatives, prolonged use is not usually recommended.
Adults, adolescents and the elderly: 1-3 sachets daily in divided doses, according to individual response.
Patients with renal insufficiency: No dosage change is necessary.
Administration:
Each sachet should be dissolved in 125 ml water.
4.3 Contraindications
Qugo Powder for Oral Solution / Macrogol compound powder for oral solution is contraindicated in intestinal obstruction or perforation caused by functional or structural disorder of the gut wall, ileus and in patients with severe inflammatory conditions of the intestinal tract (e.g. ulcerative colitis, Crohn's disease and toxic megacolon).
Hypersensitivity to the active substances or any of the excipients.
4.4 Special warnings and precautions for use
Mild adverse drug reactions are possible as indicated in Section 4.8. If patients develop any symptoms indicating shifts of fluids/electrolytes (e.g. oedema, shortness of breath, increasing fatigue, dehydration, cardiac failure) Qugo Powder for Oral Solution / Macrogol compound powder for oral solution should be stopped immediately and electrolytes measured and any abnormality should be treated appropriately.
The orange flavour in Qugo Powder for Oral Solution/ Macrogol compound powder for oral solution contains glucose. Patients with rare glucose-galactose malabsorption should not take this medicine.
The orange and the lemon lime flavour contain sulphur dioxide (E220), which may rarely cause severe hypersensitivity reactions and bronchospasm.
4.5 Interaction with other medicinal products and other forms of interaction
Macrogol 3350 raises the solubility of medicinal products that are soluble in alcohol and relatively insoluble in water. It is a theoretical possibility that absorption of these drugs could be reduced transiently.
There have been isolated reports of decreased efficacy with some concomitantly administered medicinal products, e.g. anti-epileptics.
4.6 Fertility, pregnancy and lactation
There is no experience with the use of Qugo Powder for Oral Solution / Macrogol compound powder for oral solution during pregnancy and lactation and it should only be used if considered essential by the physician.
4.7 Effects on ability to drive and use machines
Qugo Powder for Oral Solution / Macrogol compound powder for oral solution has no influence on the ability to drive and use machines.
4.8 Undesirable effects
Immune System Disorders:
Allergic reactions, including anaphylactic reaction. Other symptoms of allergic reactions include dyspnoea, urticaria and pruritus.
Gastro-intestinal Disorders:
Potential gastro-intestinal effects that may occur include abdominal distension and pain, anal discomfort, flatulence, vomiting, borborygmi and nausea.
These reactions may occur as a consequence of expansion of the contents of the gastrointestinal tract, and an increase in motility due to the pharmacologic effects of Qugo Powder for Oral Solution/Macrogol compound powder for oral solution.
Mild diarrhoea may also occur, but normally resolves after dose reduction.
Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard
By reporting side effects you can help provide more information on the safety of this medicine.
4.9 Overdose
Severe distension or pain can be treated using nasogastric aspiration. Vomiting or diarrhoea may induce extensive fluid loss, possibly leading to electrolyte disturbances that should be treated appropriately.
5 PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Osmotically acting laxatives.
ATC code: A06A D65
Macrogol 3350 induces a laxative effect through its osmotic action in the gut. It increases the stool volume, which triggers colon motility via neuromuscular pathways. The physiological consequence is an improved propulsive colonic transportation of the softened stools and a facilitation of the defaecation. Electrolytes combined with macrogol 3350 are exchanged across the intestinal barrier (mucosa) with serum electrolytes and excreted in faecal water without net gain or loss of sodium, potassium and water.
Clinical studies using the listed active substances for the treatment of chronic constipation have shown that the dose required to produce normally formed stools tends to decrease over time. Many patients, respond to between one and two sachets a day, but this dose should be adjusted depending on individual response.
5.2 Pharmacokinetic properties
Macrogol 3350 is virtually unabsorbed from the gastro-intestinal tract and is excreted, unaltered, in faeces. Any macrogol 3350 that is absorbed is excreted via the urine.
5.3 Preclinical safety data
Preclinical studies provide evidence that macrogol 3350 has no significant systemic toxicity potential, although no tests of its effects on reproduction or genotoxicity have been conducted.
There are no long-term animal toxicity or carcinogenicity studies involving macrogol 3350, although there are toxicity studies using high levels of orally administered high-molecular weight macrogols that provide evidence of safety at the recommended therapeutic dose.
6 PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Colloidal anhydrous silica Saccharin sodium
Orange flavour (Orange flavour contains: flavouring substances and flavouring preparations, maltodextrin, acacia gum, alpha-tocopherol)
Lemon lime flavour (Lemon lime flavour contains: flavouring preparations, maltodextrin, mannitol, gluconolactone, sorbitol (E420), acacia gum, colloidal anhydrous silica).
6.2 Incompatibilities
Not applicable
6.3 Shelf life
36 months
Reconstituted solution: 24 hours
6.4 Special precautions for storage
Sachet: Do not store above 25°C
Reconstituted solution: Store covered in a refrigerator (2°C to 8°C)
6.5 Nature and contents of container
The sachet is composed of paper, polyethylene/ methacrylic acid co-polymer and aluminium.
Sachets are packed in cartons of 2, 6, 8, 10, 20, 30, 50, 60 (2x30) and 100 (2x50).
Not all pack sizes may be marketed.
6.6 Special precautions for disposal
After 24 hours, any unused solution should be discarded.
7 MARKETING AUTHORISATION HOLDER
Ennogen Pharma Ltd.
Unit G4, Riverside Way Riverside Industrial Estate Dartford DA1 5BS United Kingdom
8 MARKETING AUTHORISATION NUMBER(S)
PL 40147/0089
9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE
AUTHORISATION
29/11/2013
10 DATE OF REVISION OF THE TEXT
24/07/2014